These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22655066)

  • 21. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses.
    Simmons CP; Hussell T; Sparer T; Walzl G; Openshaw P; Dougan G
    J Immunol; 2001 Jan; 166(2):1106-13. PubMed ID: 11145691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.
    Wong TM; Petrovsky N; Bissel SJ; Wiley CA; Ross TM
    Hum Vaccin Immunother; 2016 Aug; 12(8):2096-2105. PubMed ID: 27215855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants.
    Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Jung YJ; Jeeva S; Kwon YM; Seong BL; Kang SM
    Antiviral Res; 2019 Aug; 168():100-108. PubMed ID: 31150678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression differences in lungs of mice during secondary immune responses to respiratory syncytial virus infection.
    Schuurhof A; Bont L; Pennings JL; Hodemaekers HM; Wester PW; Buisman A; de Rond LC; Widjojoatmodjo MN; Luytjes W; Kimpen JL; Janssen R
    J Virol; 2010 Sep; 84(18):9584-94. PubMed ID: 20592085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RSV recombinant candidate vaccine G1F/M2 with CpG as an adjuvant prevents vaccine-associated lung inflammation, which may be associated with the appropriate types of immune memory in spleens and lungs.
    Li N; Zhang L; Zheng B; Li W; Liu J; Zhang H; Zeng R
    Hum Vaccin Immunother; 2019; 15(11):2684-2694. PubMed ID: 31021703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
    Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).
    Hancock GE; Heers KM; Smith JD; Scheuer CA; Ibraghimov AR; Pryharski KS
    Vaccine; 2001 Sep; 19(32):4874-82. PubMed ID: 11535341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.
    O'Konek JJ; Makidon PE; Landers JJ; Cao Z; Malinczak CA; Pannu J; Sun J; Bitko V; Ciotti S; Hamouda T; Wojcinski ZW; Lukacs NW; Fattom A; Baker JR
    Hum Vaccin Immunother; 2015; 11(12):2904-12. PubMed ID: 26307915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.
    Céspedes PF; Rey-Jurado E; Espinoza JA; Rivera CA; Canedo-Marroquín G; Bueno SM; Kalergis AM
    Vaccine; 2017 Feb; 35(5):757-766. PubMed ID: 28065474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M; Wilschut J; de Haan A
    Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia.
    Olson MR; Hartwig SM; Varga SM
    J Immunol; 2008 Dec; 181(11):7958-68. PubMed ID: 19017987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection.
    Harker JA; Lee DC; Yamaguchi Y; Wang B; Bukreyev A; Collins PL; Tregoning JS; Openshaw PJ
    J Virol; 2010 May; 84(10):5294-302. PubMed ID: 20200251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus.
    Riffault S; Meyer G; Deplanche M; Dubuquoy C; Durand G; Soulestin M; Castagné N; Bernard J; Bernardet P; Dubosclard V; Bernex F; Petit-Camurdan A; Deville S; Schwartz-Cornil I; Eléouët JF
    Vaccine; 2010 May; 28(21):3722-34. PubMed ID: 20307593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neonatal immunization with respiratory syncytial virus glycoprotein fragment induces protective immunity in the presence of maternal antibodies in mice.
    Noh Y; Shim BS; Cheon IS; Rho S; Kim HJ; Choi Y; Kang CY; Chang J; Song MK; Kim JO
    Viral Immunol; 2013 Aug; 26(4):268-76. PubMed ID: 23869549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
    Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice.
    Kamphuis T; Meijerhof T; Stegmann T; Lederhofer J; Wilschut J; de Haan A
    PLoS One; 2012; 7(5):e36812. PubMed ID: 22590614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine.
    Klinguer-Hamour C; Libon C; Plotnicky-Gilquin H; Bussat MC; Revy L; Nguyen T; Bonnefoy JY; Corvaïa N; Beck A
    Vaccine; 2002 Jun; 20(21-22):2743-51. PubMed ID: 12034101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.
    Lee Y; Lee YT; Ko EJ; Kim KH; Hwang HS; Park S; Kwon YM; Kang SM
    Hum Vaccin Immunother; 2017 Nov; 13(11):2594-2605. PubMed ID: 28854003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
    Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
    Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.